Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Idraparinux showed no clear difference in recurrent venous thromboembolism compared with standard therapy (low certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Idraparinux showed no clear difference in all‐cause mortality compared with standard therapy (low certainty).
1 finding from 1 review
Heparin‐induced thrombocytopaenia · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether idraparinux changes all harmful effects compared with standard therapy (very low certainty).
1 finding from 1 review
All‐cause mortality · people with cancer with VTE receiving secondary prophylaxis
Idraparinux secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review
Recurrent VTE · people with cancer with VTE receiving secondary prophylaxis
Idraparinux secondary prophylaxis showed no clear difference in recurrent VTE compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Major bleeding · people with cancer with VTE receiving secondary prophylaxis
Idraparinux secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · people with cancer with VTE receiving secondary prophylaxis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · people with cancer with VTE receiving secondary prophylaxis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether low molecular weight heparin and idraparinux changes recurrent venous thromboembolism compared with standard therapy (very low certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Heparin‐induced thrombocytopaenia · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found